KLU156

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

14 competitors in Plasmodium Falciparum Malaria

#DrugCompanyPhaseTrials

1

Aralen

Sanofi

Approved

—2

Avandia

Jazz Pharmaceuticals

Approved

—3

Methylthioninium Chloride

PProvepharm SAS

Approved

—4

Aldara

BBausch Health Americas, Inc.

Approved

—5

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Approved

—6

Mepron

GGlaxo Dba Glaxosmithkline

Approved

—7

Trental

VValidus Pharmaceuticals

Approved

—8

Lariam

UUnited BioPharma

Approved

—9

Camoquin Hydrochloride

PParkedale

Approved

—10

INE963

Novartis

Phase 2

2Show 5 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Plasmodium falciparum malaria2 trials

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

Recruiting·Novartis·Phase 2·NCT05750628·327 enrolled

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

Completed·Novartis·Phase 2·NCT07235033·60 enrolled

Malaria1 trial

Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

Completed·Novartis·Phase 3·NCT05842954·1,720 enrolled

Uncomplicated Plasmodium Falciparum Malaria1 trial

A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria

Recruiting·Novartis·Phase 2·NCT07811908·120 enrolled

Details

Drug Info

Related News